NASDAQ: TARAProtara Therapeutics Inc Stock
$2.87-0.03 (-1.03%)
Updated May 7, 2024
TARA Price
$2.87
Fair Value Price
$3.01
Market Cap
$59.09M
52 Week Low
$1.04
52 Week High
$5.24
P/E
-0.77x
P/B
1.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$42.47M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$35M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TARA Overview
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TARA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TARA ($2.87) is undervalued by 4.68% relative to our estimate of its Fair Value price of $3.01 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TARA ($2.87) is not significantly undervalued (4.68%) relative to our estimate of its Fair Value price of $3.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TARA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TARA due diligence checks available for Premium users.
Be the first to know about important TARA news, forecast changes, insider trades & much more!
TARA News
Valuation
TARA fair value
Fair Value of TARA stock based on Discounted Cash Flow (DCF)
Price
$2.87
Fair Value
$3.01
Undervalued by
4.68%
TARA ($2.87) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TARA ($2.87) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TARA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TARA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.77x
Industry
4.02x
Market
32.4x
TARA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.01x
Industry
6.06x
TARA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TARA's financial health
Profit margin
Revenue
$0.0
Net Income
-$11.1M
Profit Margin
0%
TARA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$68.1M
Liabilities
$9.7M
Debt to equity
0.17
TARA's short-term assets ($57.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TARA's short-term assets ($57.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TARA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TARA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.4M
Investing
$23.1M
Financing
-$76.0k
TARA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TARA vs Biotech Stocks
Protara Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.